CLAIMS

What is claimed is:

1. Use of cannabinoid containing plant extracellular vesicles (CPEVs) in the manufacture of a medicament for ~~A method for~~ treating a brain cancer in a subject in need, ~~comprising administering to the subject in need~~ wherein a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs) is to be administered to the subject.

2. The ~~method~~use of claim 1, wherein the ~~composition~~ medicament is to be administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

3. The ~~method~~use of claims 1 or 2, wherein the CPEVs are to be administered intranasally.

4. The ~~method~~use of any of claims 1-3, wherein ~~the administering comprises administering~~ the CPEVs are to be administered intranasally using a nasal delivery device selected from the group consisting of an intranasal inhaler, an intranasal spray device, an atomizer, a nebulizer, a metered dose inhaler (MDI), a pressurized dose inhaler, an insufflator, a unit dose container, a pump, a dropper, a nasal spray bottle, a squeeze bottle and a bi-directional device.

5. The ~~method~~use of any of claims 1-4, wherein the medicament is to be ~~further comprising co-administering~~ co-administered with an adjunct cancer therapy protocol.

6. The ~~method~~use of claim 5, wherein the adjunct cancer therapy protocol comprising treating the mammal with radiation before, during, or after the administration of the CPEVs

7. The ~~method~~use of claim 5, wherein the adjunct cancer therapy protocol comprising an additional chemotherapeutic agent.

8. A composition comprising CPEVs and a pharmaceutically acceptable carrier.

9. The composition of claim 8, wherein the pharmaceutically acceptable carrier comprises an excipient for intranasal delivery.

10. A device comprising a container, wherein a CPEV composition is disposed within said container, and a spout associated with the container that is configured for insertion into a nostril of a subject in need.

11. Use of cannabinoid containing plant extracellular vesicles (CPEVs) in the manufacture of a medicament ~~A method~~ for treating a neurodegenerative disease in a subject in need, ~~comprising administering to the subject in need~~ wherein a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs) is to be administered to the subject.

12. The ~~method~~use of claim 11, wherein the composition is to be administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

13. The ~~method~~use of claim 11, wherein the neurodegenerative disease comprises stroke, Alzheimer's disease, ALS, MS, Parkinson's disease, traumatic brain injury, or aging.

14. Use of cannabinoid containing plant extracellular vesicles (CPEVs) in the manufacture of a medicament ~~A method~~ for treating a CNS injury in a subject in need, ~~comprising administering to the subject in need~~ wherein a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs) is to be administered to the subject.

15. The ~~method~~use of claim 14, wherein the ~~composition~~ medicament is to be administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

16. Use of cannabinoid containing plant extracellular vesicles (CPEVs) in the manufacture of a medicament~~A method~~ for treating an inflammatory condition in a subject in need, ~~comprising administering to the subject in need~~ wherein a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs) is to be administered to the subject.

17. The ~~method~~use of claim 16, wherein the ~~composition~~ medicament is to be administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

18. Use of cannabinoid containing plant extracellular vesicles (CPEVs) in the manufacture of a medicament~~A method~~ for augmenting function of a CNS in a subject, ~~comprising administering to the subject in need~~ wherein a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs) is to be administered to the subject.

19. The ~~method~~use of claim 18, wherein the ~~composition~~medicament is to be administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

20. A method of making csPEVs comprising

obtaining PEVs from a Cannabis spp.;- and

loading the PEVs with an exogenous payload.

21. A composition comprising csPEVs loaded with an exogenous payload.

~~22. A method of delivering a payload to a subject comprising administering an effective amount of the composition of claim 21 to the subject.~~

~~23. The method of claim 22, wherein administering comprises intranasal delivery or parenteral delivery of the composition.~~

~~24. The method of claim 23, wherein the composition is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.~~

~~25~~22. A device comprising a container, wherein an amount of the composition of claim 21 is disposed within said container.

~~26~~23. The device of claim ~~25~~22, further comprising a spout associated with the container that is configured for insertion into a nostril of a subject in need.

~~27~~24. The ~~method~~use of any of claims 1-7, wherein the CPEVs contain CBD-A, CBG-A, THC-A, CBD, and THC at 69.1 ± 2.1%, 19.1 ± 1.6%, 6.5 ± 0.54%, 4.75 ± 0.26%, and 0.5 ± 0.3%~~,~~ of total cannabinoids, respectively.

~~28~~25. A composition of claim 8, wherein the CPEVs contain CBD-A, CBG-A, THC-A, CBD, and THC at 69.1 ± 2.1%, 19.1 ± 1.6%, 6.5 ± 0.54%, 4.75 ± 0.26%, and 0.5 ± 0.3%~~,~~ of total cannabinoids, respectively.

~~29~~26. The ~~method~~use of any of claims 11-19, wherein the CPEVs contain CBD-A, CBG-A, THC-A, CBD, and THC at 69.1 ± 2.1%, 19.1 ± 1.6%, 6.5 ± 0.54%, 4.75 ± 0.26%, and 0.5 ± 0.3%~~,~~ of total cannabinoids, respectively.